Form 8-K - Current report:
SEC Accession No. 0000950170-24-125940
Filing Date
2024-11-13
Accepted
2024-11-13 07:31:21
Documents
13
Period of Report
2024-11-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20241111.htm   iXBRL 8-K 48822
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 145425
3 GRAPHIC img46940271_0.jpg GRAPHIC 249092
  Complete submission text file 0000950170-24-125940.txt   668684

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20241111.xsd EX-101.SCH 25989
15 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20241111_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 241451187
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)